文献速递心脑血管急症消化、代谢与肾脏急症

匹伐他汀预防HIV感染者的心血管疾病

Pitavastatin to Prevent Cardiovascular Disease in HIV Infection.
PubMed 文献 · N Engl J Med · 2023-07-23
一句话结论HIV感染者接受匹伐他汀钙4mg/日,中位随访5.1年主要不良心血管事件风险低于安慰剂(HR 0.65)。

这项3期试验随机分配7769例接受抗逆转录病毒治疗、心血管疾病风险低至中度的HIV感染者,每日服用匹伐他汀钙4 mg或安慰剂。主要终点为主要不良心血管事件复合终点。中位随访5.1年时因疗效提前终止,匹伐他汀组主要不良心血管事件发生率为4.81/1000人年,安慰剂组为7.32/1000人年(HR 0.65;95%CI 0.48-0.90;P=0.002)。肌肉相关症状匹伐他汀组91例(2.3%)vs 安慰剂组53例(1.4%),糖尿病分别为206例(5.3%)vs 155例(4.0%)。

要点

  • HIV感染者接受匹伐他汀钙4 mg/日,主要不良心血管事件发生率4.81/1000人年 vs 安慰剂7.32/1000人年(HR 0.65;95%CI 0.48-0.90;P=0.002)。
  • 试验在中位随访5.1年时因疗效提前终止,提示获益在中位5.1年内即可观察到。
  • 肌肉相关症状匹伐他汀组91例(2.3%)vs 安慰剂组53例(1.4%);糖尿病206例(5.3%)vs 155例(4.0%)。
  • 入组人群为接受抗逆转录病毒治疗、心血管疾病风险低至中度的HIV感染者,中位年龄50岁,中位CD4计数621个/mm³。

适用人群与场景

  • HIV感染者,正在接受抗逆转录病毒治疗,心血管疾病风险为低至中度。
  • 中位年龄50岁(四分位距45-55);中位CD4计数621个/mm³(四分位距448-827);有数据者中HIV RNA低于定量下限者5250/5997例(87.5%)。

处置流程与药物剂量

  • 匹伐他汀钙4 mg,每日口服,用于HIV感染者心血管疾病的一级预防(研究方案剂量)。

研究设计与关键结果

  • 3期随机对照试验,7769例接受抗逆转录病毒治疗、心血管疾病风险低至中度的HIV感染者,随机接受匹伐他汀钙4 mg/日或安慰剂。
  • 主要终点为主要不良心血管事件复合终点(心血管死亡、心肌梗死、因不稳定性心绞痛住院、卒中、短暂性脑缺血发作、外周动脉缺血、血运重建或原因不明死亡)。
  • 中位随访5.1年(四分位距4.3-5.9)时因疗效提前终止;主要不良心血管事件发生率匹伐他汀组4.81/1000人年 vs 安慰剂组7.32/1000人年(HR 0.65;95%CI 0.48-0.90;P=0.002)。
  • 肌肉相关症状:匹伐他汀组91例(2.3%)vs 安慰剂组53例(1.4%);糖尿病:匹伐他汀组206例(5.3%)vs 安慰剂组155例(4.0%)。

证据类型、等级与局限

  • 证据类型:3期随机对照试验(REPRIEVE,ClinicalTrials.gov NCT02344290)。
  • 由美国国立卫生研究院等资助。

对床旁实践的改变

  • 作者结论:接受匹伐他汀的HIV感染者在中位随访5.1年内主要不良心血管事件风险低于安慰剂组。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The risk of cardiovascular disease is increased among persons with human immunodeficiency virus (HIV) infection, so data regarding primary prevention strategies in this population are needed.

METHODS: In this phase 3 trial, we randomly assigned 7769 participants with HIV infection with a low-to-moderate risk of cardiovascular disease who were receiving antiretroviral therapy to receive daily pitavastatin calcium (at a dose of 4 mg) or placebo. The primary outcome was the occurrence of a major adverse cardiovascular event, which was defined as a composite of cardiovascular death, myocardial infarction, hospitalization for unstable angina, stroke, transient ischemic attack, peripheral arterial ischemia, revascularization, or death from an undetermined cause.

RESULTS: The median age of the participants was 50 years (interquartile range, 45 to 55); the median CD4 count was 621 cells per cubic millimeter (interquartile range, 448 to 827), and the HIV RNA value was below quantification in 5250 of 5997 participants (87.5%) with available data. The trial was stopped early for efficacy after a median follow-up of 5.1 years (interquartile range, 4.3 to 5.9). The incidence of a major adverse cardiovascular event was 4.81 per 1000 person-years in the pitavastatin group and 7.32 per 1000 person-years in the placebo group (hazard ratio, 0.65; 95% confidence interval [CI], 0.48 to 0.90; P = 0.002). Muscle-related symptoms occurred in 91 participants (2.3%) in the pitavastatin group and in 53 (1.4%) in the placebo group; diabetes mellitus occurred in 206 participants (5.3%) and in 155 (4.0%), respectively.

CONCLUSIONS: Participants with HIV infection who received pitavastatin had a lower risk of a major adverse cardiovascular event than those who received placebo over a median follow-up of 5.1 years. (Funded by the National Institutes of Health and others; REPRIEVE ClinicalTrials.gov number, NCT02344290.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Grinspoon SK, Fitch KV, Zanni MV, et al. Pitavastatin to Prevent Cardiovascular Disease in HIV Infection. N Engl J Med. 2023. PMID: 37486775. doi:10.1056/NEJMoa2304146

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。